Paul Kirchgraber's most recent trade in Laboratory Corp. Of America Holdings was a trade of 4,300 Common Stock done at an average price of $216.9 . Disclosure was reported to the exchange on May 19, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Sale of securities on an exchange or to another person at price $ 216.91 per share. | 19 May 2023 | 4,300 | 12,946 (0%) | 0% | 216.9 | 932,707 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 4,300 | 0 | - | - | Non-qualified Stock Options | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 182.51 per share. | 19 May 2023 | 4,300 | 17,246 (0%) | 0% | 182.5 | 784,793 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Mar 2023 | 6,763 | 15,832 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 224.70 per share. | 30 Mar 2023 | 2,886 | 12,946 (0%) | 0% | 224.7 | 648,484 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Sale of securities on an exchange or to another person at price $ 250.58 per share. | 21 Feb 2023 | 8,000 | 9,069 (0%) | 0% | 250.6 | 2,004,675 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 182.51 per share. | 21 Feb 2023 | 3,000 | 17,069 (0%) | 0% | 182.5 | 547,530 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 3,000 | 4,300 | - | - | Non-qualified Stock Options | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 483 | 3,001 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 483 | 14,211 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 248.13 per share. | 11 Feb 2023 | 142 | 14,069 (0%) | 0% | 248.1 | 35,234 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 5,000 | 5,000 | - | - | Non-qualified Stock Options | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 1,590 | 3,484 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 560 | 13,892 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2023 | 560 | 1,894 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 244.50 per share. | 04 Feb 2023 | 164 | 13,728 (0%) | 0% | 244.5 | 40,098 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 443 | 13,473 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 443 | 2,454 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 254.99 per share. | 02 Feb 2023 | 141 | 13,332 (0%) | 0% | 255.0 | 35,954 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,007 | 4,774 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 2,007 | 9,851 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 288.78 per share. | 01 Nov 2021 | 898 | 8,953 (0%) | 0% | 288.8 | 259,324 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Sale of securities on an exchange or to another person at price $ 276.55 per share. | 06 May 2021 | 2,500 | 7,844 (0%) | 0% | 276.6 | 691,375 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2021 | 1,010 | 6,781 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2021 | 1,010 | 10,796 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 252.67 per share. | 03 Apr 2021 | 452 | 10,344 (0%) | 0% | 252.7 | 114,207 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2021 | 2,104 | 10,576 (0%) | 0% | 0 | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 251.58 per share. | 27 Mar 2021 | 790 | 9,786 (0%) | 0% | 251.6 | 198,748 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 317 | 8,565 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 317 | 7,791 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 264 | 8,335 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 264 | 8,108 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 238.26 per share. | 12 Feb 2021 | 93 | 8,472 (0%) | 0% | 238.3 | 22,158 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 238.26 per share. | 12 Feb 2021 | 87 | 8,248 (0%) | 0% | 238.3 | 20,729 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 560 | 8,372 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Feb 2021 | 560 | 8,258 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.78 per share. | 04 Feb 2021 | 187 | 8,071 (0%) | 0% | 223.8 | 41,847 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 4,600 | 4,600 | - | - | Non-qualified Stock Options | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 1,330 | 8,932 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Sale of securities on an exchange or to another person at price $ 214.14 per share. | 04 Nov 2020 | 1,500 | 7,698 (0%) | 0% | 214.1 | 321,204 | Common Stock |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 2,006 | 9,198 (0%) | 0% | - | Common Stock | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 2,006 | 7,602 | - | - | Restricted Stock Unit | |
| Labcorp | Paul Kirchgraber | CEO, Covance Drug Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 207.23 per share. | 02 Nov 2020 | 895 | 9,198 (0%) | 0% | 207.2 | 185,471 | Common Stock |